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Abstract: The reproducibility of drug absorption within a given subject as well as the
evaluation of bioavailability of two digoxin dosage forms were studied. The data
showed (a) a higher initial plasma digoxin concentration after the soft elastic gelatin
(SEG) capsule; (b) a more irregular absorption after the tablet; (c) on the average, the
coefficients of variation of individual plasma concentrations were lower after the
capsule; and (d) for the capsule, the intrasubject variations of the peak plasma concen-
trations, time of peak, area under plasma concentrations-versus-time curve (AUC),
and amount digoxin excreted in urine (A0) were on the average 60 per cent of the
variations in the tablet parameters. The ratios of AUC and A0 for capsule/tablet were
essentially unity, indicating that the amount digoxin absorbed from the 0.4-mg digoxin
SEG capsule is identical to that from a 0.5-mg standard reference tablet.
THE bioavailability of digoxin from an
oral dosage form is quite complex. Di-
goxin tablets, for instance, have shown se-
rious bioavailability deficiencies. In addi-
tion to these shortcomings there are usually
substantial inter- and intrasubject varia-
tions in bioavailability. Therefore, a rigor-
ous assessment of bioavailability of a di-
goxin dosage form may necessitate a new
investigational approach and a study de-
sign which allows for determination of var-
iations in absorption of the drug within
the same subjects. This is also important
for evaluation of a new design form which
contains a relatively insoluble drug.
Newly developed soft elastic gelatin
(SEG) capsules dosage forms have been
shown to possess superior bioavailability
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to the tablets.’7 One such capsule has been
recently developed with excellent relation-
ship between in vivo bioavailability pa-
rameters and its in vitro dissolution char-
acteristics.8 The purpose of this investi-
gation was (a) to compare the bioavaila-
bility of the newly developed digoxin SEG
capsule to standard reference tablet; and (b)
to assess the reproducibility of digoxin ab-
sorption within a given subject with respect
to peak plasma concentration, area under
plasma concentration-versus-time curve
(AUC), and amount digoxin excreted in
urine following administration of the two
dosage forms. A specifically modified four-
way crossover design allowed evaluation of
intrasubject variability of digoxin bio-
availability for each dosage form.
Methods
Twelve healthy, nonobese male subjects
22 to 29 years old and weighing 63.1 to 88.9
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kg (mean 74.2 kg) were entered in this
study and randomly assigned a number (1
through 12). All subjects signed written,
informed consent forms. They were in-
structed not to take any drugs including
enzyme-inducing agents and radiodiag-
nostic agents for a period of 30 days before
the start of the study or alcoholic beverages
for a period of seven days preceding the
initiation of or during the entire study. The
timing and nature of the diet were carefully
controlled.
Two 0.25-mg standard reference tablets
(Lanoxin, a standard lot provided by the
Biopharmaceutical Department of the
FDA, Burroughs Welicome, Lot No. 022-1)
or two 0.2-mg digoxin SEG capsules (So-
loxin, American Critical Care, Research
Lot No. 762P) were given on two separate
occasions according to Table I, where
treatment phases A1 and A2 represent the
tablets, and treatment phases B1 and B2
represent the capsules. In each case, the
drug was administered together with 240
ml water in the morning after the overnight
fast (about 10 hours). Food was allowed 4
hours after administration of the drug. Se-
rial blood samples were collected in Vacu-
tainers (containing 3.8% sodium citrate in
aqueous solution) for a period of 48 hours
following administration of the drug. After
centrifugation of the sample, plasma was
collected and immediately frozen until as-
say. A washout period of two weeks was








Treatm ent ord er (pha se no.)”
I II III IV
1 1,2,3 A, B, A2 B2
2 4,5,6 A, A2 B, B2
3 7,8,9 B, A, B, A2
4 10,11,12 B, B, A, A2
#{149}A, and
capsules.
M-0.5-mg tablets; B, and B2-0.4-mg
Digoxin concentrations in plasma and
urine were determined using a radioimmu-
noassay procedure.#{176} Each plasma con-
centration was corrected for the volume of
sodium citrate solution. The sensitivity of
this method is 0.05 ng/mI digoxin in
plasma and 2.5 ng/ml in urine. Results ob-
tained in assaying control samples, each
day that “unknowns” were run, showed ex-
cellent reproducibility. The coefficients of
variation for intraday and interday varia-
tions were 6 and 8 per cent, respectively.
The experiment was carried out accord-
ing to a modified four-way crossover study
design to compare two formulations, each
one given on two different occasions (Table
I). The bioequivalence was tested by analy-
sis of variance. The reproducibility of ab-
sorption of each digoxin formulation in
each subject was determined by two differ-
ent methods:
Method I. Paired observations from re-
peated administration of the same formula-
tion to the same subject were plotted and the
correlation was determined. While the
graph provides a vivid picture of the degree
of reproducibility of the absorption of di-
goxin, the correlation coefficient measures
only the interdependence of the paired
observation.
Method II. A good reproducibility re-
quires a high degree of positive interde-
pendence as well as large absolute agree-
ment of the data. The intrasubject varia-
tion for each formulation was estimated
from the data which were obtained for each
dosage form. The standard deviations of
the coefficient of variation were calculated
from the differences of paired observations
without correction for the mean of dif-
ferences.
Results
Figures 1 and 2 depict the plasma
concentration-versus-time profiles for the
tablet and capsule, respectively. The data
show that (a) the initial plasma digox.in






Fig. 1. Average digoxin plasma concentrations in 12 volunteers after a
single oral dose: 0.5-mg tablet in treatments A1 (L and A, (0).















are higher than for the tablet (0.5-mg dose);
(b) the absorption profiles of individual
subjects (not included) show that during










Fig. 2. Average digoxin plasma concentrations
in 12 volunteers after a single oral dose: 0.4-mg
digoxin SEG capsules in treatments B, (#{149})and B.,
(0).
absorption of digoxin from the tablet was
more irregular than from the capsule; (c)
the coefficients of variation (CV) of ob-
served plasma concentrations of digoxin
after the capsule were smaller, in 10 out of
13 samples (between 0.75 and 24 hours),
than that after the tablet (for the same 10
samples the ratio of the CVs, capsule/tab-
let, was 0.743); and (d) the plasma concen-
trations of digoxin during the second
treatment phase in each subject were al-
ways higher than during the first treat-
ment phase for both dosage forms, which is
consistent with the observed statistically
significant period effect. However, the
higher concentrations of digoxin in plasma
were not associated with any adverse
reactions.
The peak plasma digoxin concentration
for the capsule, 3.93 ng/ml, was more than
twice as high as that for the tablet, 1.88
ng/ml. The time to peak plasma concentra-
tion was significantly shorter for the cap-
sule, 0.82 hour, than for the tablet, 1.24
hour. The A UCs during the 0-24- and 0-48-
hour intervals were 11.7 and 16.6 nglml-hr,
respectively, for the capsule and 11.1 and
16.7 ng/ml-hr, respectively, for the tablet.
The amounts excreted in the urine during
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Fig. 3. Correlation of peak plasma concentrations for digoxin tablet (.) and
soft elastic gelatin capsule (A) formulations in 12 volunteers. For this as well
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Fig. 4. Correlation of 0-48-hour AUC (ng/mlhr) for digoxin tablet (.) and
soft elastic gelatin capsule (A) formulations in 12 volunteers.
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and 142 gig, respectively, for the capsule
and 100 and 146 gig, respectively, for the
tablet. These values were essentially iden-
tical for both dosage forms, with an aver-
age ratio of 1.0, indicating that the 0.5-mg
tablet dose and 0.4-mg capsule dose are
bioequivalent.
Figures 3 and 4 depict the peak plasma
concentrations and A UC in which data
from one treatment (A, and B1) are plotted
against data from the other treatment (A,
and B,). The renal digoxin clearance was
similar after both dosage forms, but there
was a significant period effect for the 0-48-
hour value. Following treatment phases A,
and A,, the average values of renal digoxin
clearance were 147 and 149 ml/min, respec-
tively. These values are consistent with
previously reported data.8”1’ Following
treatments B, and B,, the average values of
renal digoxin clearance were 154 and 137
mi/mm, a difference of 12 percent. Because
of these variations, the A UC and amount
digoxin excreted in urine were corrected for
renal clearance. Figure 5 shows the same
data as in Fig. 4 after correction of A UC for
renal clearance. Figure 6 depicts a similar capsule treatments were consistently high
plot of amount digoxin excreted in urine, and statistically significant. There were no
Table II lists the correlation coefficients such correlations with respect to the tablet
between values obtained in the two treat- treatments. In one subject (no. 9), the A UC
ments with respect to peak time, peak and amount digoxin excreted in urine after
plasma concentrations, A UC, and amount treatment A, (tablet) were very low and
of digoxin excreted in the urine. Except for almost one half the average values of other
the peak time, the correlations between the subjects. In order to lessen the possibility of
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Fig. 6. Correlation of amounts of digoxin (pg) excreted in the urine, 0-48
hours, corrected for renal clearance for digoxin tablet (5) and soft elastic
gelatin capsule (A) formulations in 12 subjects. The intercept (18.5 pig) of the















AUC 0.48 Hours Following Treatment A, AUC 048 Hour. Following Treatment
Fig. 5. Correlation of 0-48-hour A UC (ng/ml’hr) corrected for individual
renal clearance for digoxin tablet (5) and soft elastic gelatin capsule (A)
formulations in 12 subjects. The intercept of the soft elastic gelatin capsule
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TABLE II
Correlation Coefficients Between Two Treatments








Peak time 0.08 0.18 0.03 0.16
Peak level -0.14 0.69 -0.19 0.68
AUC0_,, hr(mg/fl3l hr) -0.07 0.70 0.01 0.72
AUC0_,ss,(mg/ml’ hr) -0.18 0.62 -0.05 0.64
A.. s-c, hr 0.15 0.59 0.18 0.67
A,. 0.15 0.72 0.37 0.77
* The values were not correc ted for renal clearance values.
because of data of subject 9, statistical
analysis was done with and without this
subject.
Tables III and IV summarize the inter-
and intrasubject variations, respectively,
in the pharmacokinetic parameters of di-
goxin absorption after administration of
the tablets and the capsules. On the aver-
age, the intersubject variation was slightly
smaller for the capsule; the ratio of CV of
capsule/tablet was 0.92. However, when
data from 11 subjects were considered,
there was no evidence of such a trend. The
ratios of intrasubject variations of cap-
sule/tablet were approximately 0.6 with or
without subject 9.
Discussion
A limitation of most commonly utilized
bioavailability study designs is that they
allow only for assessment of intersubject
variability as well as the common treat-
ment period and group effects. A signifi-
cant portion of the variability found, in ther-
apeutic cases, may in fact be related to
intrasubject variations in drug absorption.
The absorption from digoxin oral dosage
Intersubject Variations in Pharmacokinetic Parameters of
Digoxin Absorption After Administration of
Tablet (A) and Soft Elastic Gelatin Capsule (B) Dosage




Coe fficient of va tiations (per cent) / B, + B,
A, + A,A, A, B, B,
Peak time 68.9 20.2 51.7 26.6 0.88
Peak level 44.2 42.3 48.8 34.4 0.96
AUC0... ,, 22.2 29.2 25.6 15.7 0.80
AUCs- , 20.3 27.9 26.2 16.0 0.86
A., 0-24 hr 19.4 27.0 18.5 28.9 1.02
A,.o...s,r 18.0 26.5 19.8 23.4 0.97
* In this table, as well as in Table V, the coefficient of variations describing the
intersubject variation for each treatment are equal to (standard deviation/mean) X
100. A, and A, represent the two treatments, and B, and B, represent the two capsule
treatments.





Intrasubject Variations in Pharmacokinetic Parameters of Digoxin Absorption
After Admission of a Tablet and a Soft Elastic Gelatin Capsule
Dosage Form in 12 Normal Subjects
Pharmacokinetic
parameters








Peak time 63.9 38.3 0.60 91.4 56.8 0.62
Peak level 44.7 28.3 0.63 73.2 33.3 0.45
AUCo_c, hr 26.6 15.5 0.58 32.3 20.8 0.64
AUCo_e . 26.0 15.8 0.61 30.3 21.5 0.71
A., 0-24 hr 26.4 17.0 0.65 37.4 16.9 0.45
A,.o_45h, 21.1 12.0 0.57 23.0 15.7 0.68
* Per cent coefficient of variation calculated as described by method II.
forms in particular has been erratic and
has been a major concern in therapy. In
this study, as a part of a new oral dosage
form development, an attempt was made te
account for both inter- and intrasubject vari-
ations in absorption of digoxin from a di-
goxin SEG capsule and a standard refer-
ence tablet. The modified four-way cross-
over study used in this study allowed the
simultaneous evaluation of both the repro-
ducibility of absorption in the same subject
as well as the assessment of the bioavaila-
bility of the two digoxin dosage forms.
The absorption of the 0.4-mg capsule was
found to be much faster, producing peaks
twice as high as that of the 0.5-mg tablet. In
Intersubject Variations in Pharmacokinetic Parameters
of Digoxin after Administration of a Tablet and a
Soft Gelatin Capsule Dosage Form in Humans
Pharmacokinetic
parameters






Cmi, 22.2 16.0 0.72
Peak time 38.5 27.5 0.71
Peak level 15.3 8.1 0.53
AUCs-7 hr 16.8 13.3 0.79
A, 12.1 10.4 0.86
Single-Dose Study7
(N =7)
Peak level 24.3 13.2, 16.7* 0.62
AUC s-c, hr 26.8 13.0, 13.5 0.49
A., o..s.y 20.8 11.2,13.5 0.59
* Two sets of data representing two capsules differing in size.
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the case of both dosage forms, higher
plasma concentrations were observed dur-
ing the second treatment. This could be due
to variations in absorption within the same
subject and/or possible changes in physio-
logic factors influencing the renal excretion
of digoxin. Interestingly, a 12 per cent vari-
ation in renal clearance was found for the
capsule and not for the tablet. This indi-
cates that for the tablet the variations in
the pharmacokinetic parameters are al-
most entirely related to variations in ab-
sorption.
In general, considering the data from all
subjects, the intersubject variability was
smaller for the capsule. Excluding the data
from one subject, this variability was no
longer apparent. In this study, there was a
significant period effect which may have
obscured the existence of any intersubject
variability. Table V summarizes the inter-
subject variations in pharmacokinetic pa-
rameters from two studies3’4 which tested
digoxin SEG capsules and tablets. The data
showed significantly less variation for the
capsules.
One method to assess reproducibility of
digoxin absorption in the same subject is to
plot the data from one treatment with a
given dosage form versus the data obtained
from the second treatment with the same
dosage form. In this study, such plots for
both the standard reference tablet and the
digoxin SEG capsule were prepared with
respect to peak plasma concentration (Fig.
3), A UC0-45 hr (Figs. 4 and 5), and amount of
digoxin excreted in the urine (Fig. 6).
Ideally, each relationship should yield a
straight line with a slope of unity and an
intercept of zero. Additionally, as noted
above, the renal function may affect the
observed parameters. Therefore, the pa-
rameters were ‘also corrected for renal
effect.
The relationship between values ob-
tained in the two tablet treatments, with
respect to peak plasma concentration,
A UC, and amount of digoxin excreted in
the urine, showed no significant correla-
tions. Correction of the data for renal di-
goxin clearance did improve the correla-
tions, but they remained statistically in-
significant. These observations clearly
point out the lack of reproducibility of ab-
sorption of digoxin from the tablet in the
same subjects. In contrast, there was a sig-
nificant positive correlation between val-
ues of peak plasma digoxin concentration,
A UC, and amount of digoxin excreted in
the urine which were obtained in the two
treatments of digoxin SEG capsule (B, and
B,) in the same subject. Consistent with the
observation of possible renal effect on
bioavailability, when the individual data
were corrected for renal digoxin clearance
the correlation did improve significantly
and particularly that for the A UC became
greater (r = 0.850, P <0.001) with a slope
equal to 0.971, very close to unity. Addi-
tionally, the correlation coefficients be-
tween the ratio of peak plasma concen-
tration and A UC in treatment 1 versus the
same ratio in treatment 2 of each dosage
form were determined by Pearson’s equa-
tion.’4 These correlation coefficients were
0.589 and 0.0017 for the SEG capsule and
tablet, respectively, and were essentially
identical to the values obtained by the con-
ventional method. These results emphasize
the superiority of the capsule also in terms
of reproducibility of absorption in the same
subjects.
Another method of examination of the
intrasubject variations in absorption of di-
goxin is to compare the coefficients of vari-
ation of different pharmacokinetic param-
eters, In this study, both the inter- and
intrasubject variations in absorption are
dependent on the dosage form. The intra-
subject variations, however, do provide
more definitive information, since usually
all the factors except absorption are the
same within the same subject. As indicated
in Table IV, the intrasubject variation in
the absorption of digoxin from the capsule
was about 60 per cent of the variations
within the tablets with respect to peak
plasma digoxin concentration, time to
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peak, A UC, and amount of digoxin excreted
in the urine. These results substantiate the
poor subject-to-subject variation in absorp-
tion of digoxin from the tablet when com-
pared to the capsule.
The results of this study are consistent
with those reported in the literature com-
paring a tablet with a different brand of
digoxin SEG capsule. In one study, stead y-
state plasma digoxin concentration after a
tablet was compared with that after a SEG
capsule in 20 patients.’3 There were signifi-
cantly greater variations between two se-
rum digoxin concentrations in the same
subjects after the tablet (18 per cent) than
after the capsule (11 per cent). In another
study, variations in steady-state plasma
concentrations were examined after ad-
ministration of a tablet and a capsule in 10
normal subjects.4 Using three steady-state
plasma digoxin concentrations in the same
subject, coefficients of variation of 22 and
16 per cent were observed for the tablet and
capsule, respectively.
A single- and multiple-dose study carried
out by other investigators on the same
brand of tablet and capsule showed essen-
tially identical results, i.e., the bioavailabil-
ity of the capsule is superior to that of the
tablet.’5 The data described in this study
and in the literature indicate that the ref-
erence tablet which is used as a standard
dosage form to test oral absorption may
produce considerable variability in clinical
response due to the variations in its in vivo
absorption. Thus, from the clinical stand-
point, the use of a dosage form that mini-
mizes the intrapatient variations will also
result in improved therapy and fewer del-
eterious effects.
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